Prognostic Value of PCNA , c-erbB-2 , c-fos in Patients with Non-small Cell Lung Cancer / 대한암학회지
Journal of the Korean Cancer Association
;
: 678-685, 1999.
Article
in Korean
| WPRIM
| ID: wpr-126874
ABSTRACT
PURPOSE:
Oncogenes, tumor suppressor genes, and growth variables of tumors are important in the assessment of prognosis in lung cancer. The expression of PCNA, c-erbB-2 (HER-2/neu), and c-fos oncoprotein and their prognostic implications in surgically resected patients with non-small cell lung cancer were evaluated. MATERIALS ANDMETHODS:
Seventy patients with non-small cell lung cancer were included and PCNA, c-erbB-2 and c-fos overexpression were evaluated by immunohistochemical stain using paraffin-embedded tissue.RESULTS:
The mean proportion of PCNA positive cells was 18.6%, and there was no significant difference according to cell type and stage. The median survival time was significantly shorter in the group with high PCNA expression (>10%) as compared with the group with low PCNA expression (<10%) (37 months vs 16 months). Four (6.3%) of 64 cases demonstrated c-erbB-2 positivity. These were all adenocarcinoma cases. c-fos protein was only rarely overexpressed (1/51).CONCLUSION:
PCNA expression was shown to be a useful prognostic parameter in resected non-small cell lung cancer while c-erbB-2 and c-fos oncoprotein were infrequently expressed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Oncogenes
/
Prognosis
/
Adenocarcinoma
/
Genes, Tumor Suppressor
/
Carcinoma, Non-Small-Cell Lung
/
Proliferating Cell Nuclear Antigen
/
Lung Neoplasms
Type of study:
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Cancer Association
Year:
1999
Type:
Article
Similar
MEDLINE
...
LILACS
LIS